RPG Life Sciences launches Naprosyn ES in India via Archerchem partnership

Regulatory Product ApprovalBusiness Updates View source PDF

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-4.2%1-day move

₹2861.10

prior close

₹2843.50

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.4+1.0——-4.2+3.8+2.4-0.4+5.9+4.3————

Up moveDown movePending

AI summary

RPG Life Sciences has partnered with Archerchem Healthcare to launch Naprosyn ES, a combination of Naproxen and Esomeprazole, for the first time in India. It targets patients needing long-term NSAID therapy who face gastrointestinal risks. RPG LS will exclusively market and distribute the product pan-India, while Archerchem will be the exclusive supplier. The launch expands RPG LS chronic therapy portfolio and leverages the Naprosyn brand legacy.

Likely market impact

Strengthens chronic therapy portfolio and extends the Naprosyn brand. Revenue impact not quantified but adds to domestic growth pipeline.